| HOME >> BIOLOGY >> TECHNOLOGY |
Increase/(Decrease) in
income tax, surcharge tax
and dividends withholding tax 588,686 622,305
Increase/(Decrease) in
other payables and
accruals, and value added
tax payable (136,326) 130,688
Increase/(Decrease) in
interest payables (121,402) --
NET CASH PROVIDED BY
OPERATING ACTIVITIES $ 8,347,674 $ 7,761,471
CASH FLOWS USED IN
INVESTING ACTIVITIES
Purchases of fixed assets (7,193,855) (533,080)
CASH FLOWS FROM FINANCING
ACTIVITIES
Effect of exchange rate
changes on cash $ 740,436 $ 474,448
NET INCREASE IN CASH AND
CASH EQUIVALENTS BALANCES $ 1,894,255 $ 7,702,839
CASH AND CASH EQUIVALENTS
BALANCES AT BEGINNING OF
PERIOD 64,310,448 26,992,025
CASH AND CASH EQUIVALENTS
BALANCES AT END OF PERIOD $ 66,204,703 $ 34,694,864
CHINA-BIOTICS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL DATA
Three Months ended Three Months ended
Non-GAAP Net income June 30, 2008 June 30, 2007
Net Income (Loss) Net Income Net Income
Adjusted Amount 4,475,750 $ 3,540,233
Adjustments
Non-cash loss from change
in fair value of
convertible bonds $ 1,239,000 --
Amount per consolidated statement
of operations $ 3,236,750 $ 3,540,233
For more information, please contact:
CCG Investor Relations
'/>"/>
| SOURCE China-Biotics, Inc. Copyright©2008 PR Newswire. All rights reserved |